Key statistics
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 12.30m |
Free float | 6.32m |
P/E (TTM) | -- |
Market cap | 72.69m USD |
EPS (TTM) | -6.21 USD |
--
More ▼
Announcements
- Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
- Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
- Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
- Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
- Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
- Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
- Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
More ▼